Sign In
Buy ELUT
Elutia Earnings Calls
| Release date | May 14, 2026 |
| EPS estimate | -$0.150 |
| EPS actual | -$0.170 |
| EPS Surprise | -13.33% |
| Revenue estimate | 3M |
| Revenue actual | 3.114M |
| Revenue Surprise | 3.80% |
| Release date | Mar 11, 2026 |
| EPS estimate | -$0.140 |
| EPS actual | -$0.140 |
| Revenue estimate | 3.3M |
| Revenue actual | 3.271M |
| Revenue Surprise | -0.88% |
| Release date | Nov 06, 2025 |
| EPS estimate | -$0.155 |
| EPS actual | -$0.0100 |
| EPS Surprise | 93.55% |
| Revenue estimate | 3.3M |
| Revenue actual | 3.323M |
| Revenue Surprise | 0.697% |
| Release date | Aug 14, 2025 |
| EPS estimate | -$0.170 |
| EPS actual | -$0.260 |
| EPS Surprise | -52.94% |
| Revenue estimate | 7.4M |
| Revenue actual | 6.263M |
| Revenue Surprise | -15.36% |
Last 4 Quarters for Elutia
Below you can see how ELUT performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 14, 2025 |
| Price on release | $2.15 |
| EPS estimate | -$0.170 |
| EPS actual | -$0.260 |
| EPS surprise | -52.94% |
| Date | Price |
|---|---|
| Aug 08, 2025 | $2.01 |
| Aug 11, 2025 | $1.97 |
| Aug 12, 2025 | $1.99 |
| Aug 13, 2025 | $2.16 |
| Aug 14, 2025 | $2.15 |
| Aug 15, 2025 | $2.02 |
| Aug 18, 2025 | $2.02 |
| Aug 19, 2025 | $2.02 |
| Aug 20, 2025 | $2.12 |
| 4 days before | 6.97% |
| 4 days after | -1.40% |
| On release day | -6.05% |
| Change in period | 5.47% |
| Release date | Nov 06, 2025 |
| Price on release | $0.94 |
| EPS estimate | -$0.155 |
| EPS actual | -$0.0100 |
| EPS surprise | 93.55% |
| Date | Price |
|---|---|
| Oct 31, 2025 | $0.91 |
| Nov 03, 2025 | $0.94 |
| Nov 04, 2025 | $0.92 |
| Nov 05, 2025 | $0.96 |
| Nov 06, 2025 | $0.94 |
| Nov 07, 2025 | $0.90 |
| Nov 10, 2025 | $0.86 |
| Nov 11, 2025 | $0.82 |
| Nov 12, 2025 | $0.740 |
| 4 days before | 3.61% |
| 4 days after | -21.44% |
| On release day | -5.00% |
| Change in period | -18.61% |
| Release date | Mar 11, 2026 |
| Price on release | $1.09 |
| EPS estimate | -$0.140 |
| EPS actual | -$0.140 |
| Date | Price |
|---|---|
| Mar 05, 2026 | $1.11 |
| Mar 06, 2026 | $1.09 |
| Mar 09, 2026 | $1.17 |
| Mar 10, 2026 | $1.09 |
| Mar 11, 2026 | $1.09 |
| Mar 12, 2026 | $1.15 |
| Mar 13, 2026 | $1.08 |
| Mar 16, 2026 | $1.07 |
| Mar 17, 2026 | $1.09 |
| 4 days before | -1.80% |
| 4 days after | 0% |
| On release day | 5.50% |
| Change in period | -1.80% |
| Release date | May 14, 2026 |
| Price on release | $1.04 |
| EPS estimate | -$0.150 |
| EPS actual | -$0.170 |
| EPS surprise | -13.33% |
| Date | Price |
|---|---|
| May 08, 2026 | $1.01 |
| May 11, 2026 | $1.06 |
| May 12, 2026 | $1.05 |
| May 13, 2026 | $1.05 |
| May 14, 2026 | $1.04 |
| May 15, 2026 | $1.03 |
| May 18, 2026 | $1.10 |
| May 19, 2026 | $1.12 |
| May 20, 2026 | $1.18 |
| 4 days before | 2.97% |
| 4 days after | 13.46% |
| On release day | -0.96% |
| Change in period | 16.83% |
Elutia Earnings Call Transcript Summary of Q1 2026
Elutia reported progress toward turning into a pure‑play drug‑eluting biomatrix company focused on breast reconstruction. Management says FDA interactions have been productive and they expect NXT‑41 clearance in Q4 2026 with the drug‑eluting NXT‑41x following in H1 2027. The company brought an automated manufacturing platform online this quarter that it says enables precise, scalable drug coating and targets gross margins above 80% at scale. Commercial feedback from surgeons reinforces a concentrated, high‑value U.S. market (~$1.5 billion), high complication/infection rates (15%–20%, higher at many high‑volume centers), and limited current innovation — implying adoption could be achieved through a focused sales effort at a few hundred hospitals. Financially, Q1 net sales were $3.1M (SimpliDerm $2.1M; Cardiovascular $1.0M), adjusted gross margin improved to 67%, operating expenses were $8.2M, net loss was $7.5M, and adjusted EBITDA loss was $4.4M. Cash plus escrow totaled ~$36.5M. The company is pursuing strategic processes (SimpliDerm divestiture and inbound interest in its Cardiovascular line) to further focus resources on NXT‑41x and strengthen the balance sheet. Management highlights prior commercialization experience (sale of EluPro to Boston Scientific for $88M) as evidence of execution capability.
